Tag: Uplizna

Innovation, Research

New NMO Drug Gets FDA Nod

June 12, 2020

Via: MedPageToday

Intravenous inebilizumab (Uplizna) won approval to treat neuromyelitis optica spectrum disorder (NMOSD), the FDA announced late Thursday. The anti-CD19, B-cell depleting monoclonal antibody was approved to treat adult NMOSD patients positive for anti-aquaporin-4 (AQP4) antibodies. NMOSD is a rare, severe, […]